BACKGROUND: Sexually transmitted acute hepatitis C among HIV-positive homosexual men has been noted as an emerging epidemic. METHODS: Forty-seven patients with mainly sexually acquired, acute hepatitis C were enrolled in this prospective, multicentre trial, and 36 of these patients were treated within the acute phase of hepatitis C infection with pegylated interferon (peg-IFN) therapy. RESULTS: Early treatment resulted in sustained virological response in 61% of patients. Peg-IFN alone showed similar treatment response rates and lower incidence of anaemia compared with peg-IFN+ribavirin combination therapy. Higher treatment response rates were observed in patients treated over 48 weeks compared with 24 weeks. CONCLUSIONS: Treatment of hepatitis C in HIV-positive individuals in the acute phase of infection leads to high rates of sustained virological response. Optimal time and mode of therapy have yet to be defined.
BACKGROUND: Sexually transmitted acute hepatitis C among HIV-positive homosexual men has been noted as an emerging epidemic. METHODS: Forty-seven patients with mainly sexually acquired, acute hepatitis C were enrolled in this prospective, multicentre trial, and 36 of these patients were treated within the acute phase of hepatitis C infection with pegylated interferon (peg-IFN) therapy. RESULTS: Early treatment resulted in sustained virological response in 61% of patients. Peg-IFN alone showed similar treatment response rates and lower incidence of anaemia compared with peg-IFN+ribavirin combination therapy. Higher treatment response rates were observed in patients treated over 48 weeks compared with 24 weeks. CONCLUSIONS: Treatment of hepatitis C in HIV-positive individuals in the acute phase of infection leads to high rates of sustained virological response. Optimal time and mode of therapy have yet to be defined.
Authors: Christoph Boesecke; Patrick Ingiliz; Thomas Reiberger; Hans-Jürgen Stellbrink; Sanjay Bhagani; Emma Page; Stefan Mauss; Thomas Lutz; Esther Voigt; Marguerite Guiguet; Marc-Antoine Valantin; Axel Baumgarten; Mark Nelson; Martin Vogel; Jürgen K Rockstroh Journal: Infection Date: 2016-02 Impact factor: 3.553
Authors: Daniel S Fierer; Douglas T Dieterich; Michael P Mullen; Andrea D Branch; Alison J Uriel; Damaris C Carriero; Wouter O van Seggelen; Rosanne M Hijdra; David G Cassagnol Journal: Clin Infect Dis Date: 2013-12-13 Impact factor: 9.079
Authors: Jason Grebely; Margaret Hellard; Tanya Applegate; Kathy Petoumenos; Barbara Yeung; Jordan J Feld; William Rawlinson; Andrew R Lloyd; Jacob George; John M Kaldor; Gregory J Dore; Gail V Matthews Journal: AIDS Date: 2012-08-24 Impact factor: 4.177
Authors: Jacob Nattermann; Martin Vogel; Hans Dieter Nischalke; Mark Danta; Stefan Mauss; Hans-Jörg Stellbrink; Axel Baumgarten; Christoph Mayr; Raffaele Bruno; Cristina Tural; Gerd Klausen; Bonaventura Clotet; Uwe Naumann; Thomas Lutz; Michael Rausch; Knud Schewe; Bernhard Bienek; Georg Haerter; Tilman Sauerbruch; Juergen K Rockstroh; Ulrich Spengler Journal: J Infect Dis Date: 2011-01-21 Impact factor: 5.226
Authors: Gregory J Dore; Margaret Hellard; Gail V Matthews; Jason Grebely; Paul S Haber; Kathy Petoumenos; Barbara Yeung; Philippa Marks; Ingrid van Beek; Geoffrey McCaughan; Peter White; Rosemary French; William Rawlinson; Andrew R Lloyd; John M Kaldor Journal: Gastroenterology Date: 2009-09-24 Impact factor: 22.682
Authors: Bing Zhang; Nghia H Nguyen; Brittany E Yee; Benjamin Yip; Walid S Ayoub; Glen A Lutchman; Mindie H Nguyen Journal: Intervirology Date: 2015-09-25 Impact factor: 1.763